Cerebellar ataxia due to procainamide toxicity

Area of Science:

• Pharmacology
• Neuroscience
• Cardiology

Background:

• Procainamide hydrochloride is an antiarrhythmic drug used to treat ventricular tachycardia.
• Established therapeutic ranges for procainamide hydrochloride may be insufficient for programmed ventricular stimulation.

Observation:

• A patient developed acute cerebellar ataxia while undergoing high-dose procainamide hydrochloride therapy.
• The onset of ataxia correlated with a significant elevation in serum procainamide hydrochloride levels.

Findings:

• High-dose procainamide hydrochloride can lead to neurological toxicity, specifically cerebellar ataxia.
• Serum drug monitoring is crucial as therapeutic levels may exceed previously established ranges.

Implications:

• Clinicians should consider neurological side effects when prescribing high-dose procainamide hydrochloride.
• Further research is needed to define optimal therapeutic and toxic ranges for procainamide hydrochloride in specific patient populations.